Morinaga Milk Industry is one of Japan's leading dairy companies and a pioneer in microbiome science. Inspired by the discovery that bifidobacteria are the predominant bacteria in the intestines of breast-fed infants, Morinaga began its bifidobacteria research in the 1960s. In 1969, the company discovered its flagship strain, Bifidobacterium longum BB536, from a healthy breast-fed infant.

Today, backed by over 50 years of research, Morinaga proudly presents its HRB (Human-Residential Bifidobacteria) Probiotics portfolio, featuring BB536, M-16V, M-63, B-3, and MCC1274. These science-backed probiotics support a wide range of health areas, including gut health, infant nutrition, metabolism, cognition, healthy ageing, and more.

Complementing this portfolio, Morinaga's Postbiotics, LAC-Shield and LAC-Living+, provide innovative solutions for immune and mood support across a variety of applications and life stages. Together, our HRB Probiotics and Postbiotics deliver microbiome solutions that help support health and wellbeing from infancy through healthy ageing.